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When teaching clinical undergraduates about the cause of 
atherosclerosis the lecturer will highlight risk factors such 
as smoking, hypercholesterolaemia and hypertension that 
are mutable for therapeutic benefit. If the same lecturer 
were to be talking to their science laboratory staff they 
would discuss inflammatory paradigms in the vessel wall 
that lead to lipid accumulation in monocyte-derived 
macrophages that become foam cells. Depending upon 
the local plaque microenvironment and T cell repertoire 
these monocyte-derived macrophages direct either plaque 
stability and/or resolution of inflammation through 
production of smooth muscle cell mitogens or release 
proinflammatory cytokines, matrix metalloproteinases 
and express tissue factor that promotes a disorganised, 
thrombogenic plaque with lesion progression and 
a s soc i a ted  myocard i a l  in f a rc t ion  or  s t roke  (1 ) . 
A bright student might ask whether the inflammatory 
process can be altered for therapeutic benefit? Until the 
recent publication of the Canakinumab Antiinflammatory 
Thrombosis Outcome Study (CANTOS) trial the answer 
would have been, no. So, has CANTOS really changed the 
response to, yes?
The CANTOS investigators tested the hypothesis that 
inhibiting the action of the cytokine interleukin-1 (IL-1) 
beta would have beneficial effects on a composite endpoint 
in patients with a prior myocardial infarction and a high-
sensitivity C-reactive protein (hsCRP) level that constituted 
a vascular risk (≥2 mg/L) (2). Three different doses of 
the IL-1 beta neutralising antibody Canakinumab were 
tested against placebo over 48 months. A dose-dependent 
reduction in hsCRP was demonstrated without significant 
alteration in lipid levels. There was a dose graded reduction 
in the primary endpoint of first occurrence of nonfatal 
myocardial infarction, nonfatal stroke, or cardiovascular 
death with the pre-specified, complex statistical threshold 
for primary and secondary endpoints being met with 
the 150-mg dose. There was no difference in all-cause 
mortality, however, there was a significant increase in 
infection-related deaths when all treated patients were 
compared with placebo.
The CANTOS trial targeted IL-1beta, a highly specific 
mediator of inflammation. The broader IL-1 signalling 
family has been a target for therapeutic inhibition in other 
disease areas, most commonly using the recombinant 
IL-1 receptor antagonist (IL-1ra) that inhibits both 
the active agonists in the family (IL-1 alpha and beta). 
The IL-1ra approach has had a modest benefit in overt 
inflammatory conditions such as rheumatoid arthritis (3) 
and a significant effect in anti-inflammatory conditions 
characterised by over activity of the inflammasome (4). The 
IL-1 pathway has considerable preclinical data to support 
its involvement in atherogenesis, the inflammatory response 
to fat feeding and the response to vessel wall response 
to injury (5-7). Whilst these studies, conducted as they 
were in laboratory animals have all been consistent with a 
hypothesis that IL-1 is atherogenic, human genetic studies 
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have been less consistent in their results (8,9).
Against this background CANTOS undertook an 
investigation of inhibition of IL-1beta in patients with 
prior myocardial infarction and a risk profile similar to 
prior studies investigating statins for so-called secondary 
prevention. The selection of IL-1beta inhibition alone 
(as opposed to dual IL-1alpha and beta inhibition) is one 
that makes sense in view of knowledge of the IL-1 system. 
IL-1alpha is a cytokine released at the time of cellular death 
and IL-1beta one that is released from the inflammasome 
in an agonist-induced manner. What cannot be answered is 
whether dual inhibition would have been better (or worse) 
than the reduction in clinical events demonstrated with 
IL-1beta inhibition in CANTOS.
CANTOS selected patients with a hsCRP greater 
than or equal to 2 mg/L rather than all patients with prior 
myocardial infarction. This inclusion criteria serves to 
increase inflammatory signalling available for therapeutic 
modulation, however, the absence of a treated group with 
a low hsCRP leaves the hypothesis incompletely examined 
and the question of how such patients would respond to 
therapy untested. If the hypothetical low hsCRP group had 
not responded then modulation of an innate inflammatory 
paradigm in coronary disease would have been proven using 
the models of vascular inflammation we currently hold. 
If the hypothetical low hsCRP group had responded in a 
similar manner as the high hsCRP group it would prove 
that IL-1beta was important but that hsCRP was not the 
appropriate biomarker to represent atherosclerotic instability. 
As such, the dataset is incomplete without a low hsCRP 
group. Relevant to this issue, the CANTOS investigators 
published a subset analysis which indicates that benefit 
was best achieved in patients in whom Canakinumab most 
effectively suppressed hsCRP (10). Within the limitation of 
subset analyses these additional data are supportive of the 
inflammatory hypothesis.
The CANTOS trial does indicate that IL-1beta 
inhibition reduces hsCRP in patients who entered the 
study with a hsCRP ≥2 mg/L. We can only speculate what 
is driving the raised hsCRP (other than IL-1beta). It was 
tempting to presume that the increased hsCRP would 
be primarily driven by lipids as the results of some statin 
trials suggest (11). The findings of CANTOS, however, 
dissociate lipids from hsCRP, at least in a well-treated 
group of patients on statins with higher than usual hsCRP 
levels (median hsCRP at entry was 4.1 mg/L). Nested 
within this large group of patients were some who by the 
end of the trial had presented with lung cancer—this group 
had a hsCRP of 6.0 mg/L at baseline (11). A hypothesis-
generating publication from the CANTOS trail has also 
shown that the group who made a good hsCRP response, 
classified as a median hsCRP <1.8 at 3 months, had a highly 
significant reduction in the diagnosis of incident case lung 
cancer during the trial. More than 90% of CANTOS 
subjects were current or ex-smokers (12). Therefore, the 
inflammatory drive in this group of patients is likely to be 
complex and multifactorial, and the question of the driver 
of the raised hsCRP (other than IL-1) remains one of 
speculation.
Outside of overt inflammatory illnesses inflammation is 
a response that is beneficial to a number of tissue insults. 
Modulation of inflammation has, with almost all agents used, 
come at the cost of side effects, either directly attributable 
to the reduction in inflammation/immunosuppression 
or off-target effects. One of the earliest described effects 
of IL-1 is an effect on bone marrow, to which it acts as a 
haemopoietic growth factor (13,14). Animal experiments 
consistently demonstrate a fall in white count with IL-1 
inhibition. Both neutropenia and thrombocytopenia were 
detected in treated patients in CANTOS and these findings 
translated into a small excess on infection-related deaths in 
the treated group with no overall increase in mortality. The 
numbers of cases of tuberculosis were very small and equally 
distributed across groups, however, it should be noted 
patients at high risk of infection and possible tuberculosis 
(TB) were excluded from trial entry. There a was also no 
excess of haemorrhage. These data, whilst not impacting on 
the testing of an inflammatory hypothesis in atherosclerosis, 
do impact the likelihood that this therapeutic approach 
might be implemented in this patient group. The small 
primary event reduction (about 1 per 100 patient years) 
with this side effect profile will probably require additional 
studies and positive data from another patient group with 
a higher overall event rate. Such an investigation might be 
prompted by the success of CANTOS.
CANTOS examined the effect of IL-1beta inhibition 
at least 30 days distant from a myocardial infraction over 
a 48-month period. Studies of IL-1 inhibition at the time 
of myocardial infarction have shown that the hsCRP in 
non-ST elevation (STE) acute coronary syndrome (ACS) 
patients is dramatically suppressed by IL-1 receptor 
antagonist (15). Others have shown in small studies of STE 
ACS patients IL-1 inhibition not only suppressed hsCRP 
but also had a signal suggesting favourable remodelling 
of the left ventricle (16-18). The data from CANTOS are 
for a highly specific group of patients post ACS, but the 
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question of whether the outcome for IL-1beta inhibition 
more proximate to the index ACS would be more or less 
beneficial is one that should be tested in subsequent studies. 
IL-1beta inhibition at current market-price is expensive 
and comes with an infectious side effect profile. Both aspects 
are presumably cumulative over the duration of therapy. 
Whilst the study of other secondary preventive therapies 
in cardiovascular disease have examined interventions over 
similar durations the implication is that benefits accrue with 
extended treatment. It is, however, unclear if this is the case 
for anti-inflammatory therapy in coronary disease. It might 
be, but an alternative view is that with extended, modern, 
high-dose statins and angiotensin converting enzyme (ACE) 
inhibitor treatment, the addition of anti-IL-1beta therapies 
may not accrue continued benefit. Shorter treatment 
duration might be possible at the time of heightened risk 
and plaque instability (as is undertaken with dual anti-
platelet therapy post-ACS). Outcome data from patients 
who discontinued treatment during or after the study 
might be helpful in this respect but a biological case could 
be made for studies of shorter duration therapy to assess 
whether the majority of benefit is accrued in a shorter time 
frame, presumably with lower cost and reduced incidence of 
infectious side effects.
There is no doubt that CANTOS is a trial that the 
cardiovascular world was waiting for with a high level 
of anticipation, and the positive headline result has not 
disappointed. It took years and very many statin trials to 
prove the lipid hypothesis in atherosclerosis and it will take 
more than CANTOS to prove the inflammatory hypothesis 
of coronary disease is tractable for patient benefit. More 
detail is needed from the study and will undoubtedly come 
from subsequent studies of IL-1 inhibition and other anti-
inflammatory agents in both coronary artery disease and a 
boarder spectrum of potentially inflammatory driven vascular 
diseases (19-21)—these are very welcome. Is IL-1 beta 
inhibition in coronary artery disease going to hit the clinic 
soon? Probably not, but possibly one day. More importantly 
and pressingly CANTOS has sounded the starting gun for 
anti-inflammatory therapy in coronary artery disease.
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